NEW YORK, July 1, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced that results of a

Download  full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled  in vitro  diagnostics company focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces a  partnership with the University of

NEW YORK, June 30, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced a partnership with

Download  full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled  in vitro  diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announces the public filing of a registration

Download  full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled  in vitro  diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces proposed board changes together with the

NEW YORK, June 25, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced the public filing of a

Download  full announcement Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has received a clinical laboratory

NEW YORK, June 12, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announced that it has received a

Download  full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has yesterday

Download  full announcement   Renalytix AI plc  (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that results from a